A First-in-human, Open-label Dose Escalation Followed by Dose Expansion Phase I/IIa Trial to Evaluate the Safety, Preliminary Efficacy and Pharmacokinetics of Intratumoral CyPep-1 Monotherapy and in Combination With Pembrolizumab in Patients With Advanced Solid Cancers
Latest Information Update: 28 Sep 2024
At a glance
- Drugs CyPep-1 (Primary) ; Pembrolizumab (Primary)
- Indications Advanced breast cancer; Head and neck cancer; Lymphoma; Malignant melanoma; Solid tumours; Squamous cell cancer; Triple negative breast cancer
- Focus Adverse reactions; First in man
- Acronyms CICILIA
- Sponsors Cytovation
Most Recent Events
- 13 Sep 2024 Results published in a Cytovation media release
- 13 Sep 2024 According to a Cytovation media release, company will deliver a poster presentation at ESMO 2024 from this Phase I/IIa CICILIA trial.
- 24 Jul 2024 Status changed from active, no longer recruiting to completed.